Taysha Gene Therapies (TSHA) Projected to Release Quarterly Earnings on Tuesday

Taysha Gene Therapies (NASDAQ:TSHA) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Taysha Gene Therapies to post earnings of ($0.1146) per share and revenue of $0.6180 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, analysts expect Taysha Gene Therapies to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Taysha Gene Therapies Stock Performance

TSHA stock traded up $0.15 during mid-day trading on Tuesday, hitting $5.93. 492,619 shares of the company were exchanged, compared to its average volume of 2,868,334. Taysha Gene Therapies has a 1-year low of $2.63 and a 1-year high of $7.30. The stock has a market capitalization of $1.71 billion, a PE ratio of -15.62 and a beta of 1.22. The business has a 50 day simple moving average of $6.00 and a 200-day simple moving average of $5.39. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23.

Analyst Upgrades and Downgrades

TSHA has been the subject of several research reports. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Canaccord Genuity Group upped their price objective on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a report on Monday, April 6th. BMO Capital Markets increased their price objective on Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Wall Street Zen cut shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $12.77.

Insider Transactions at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the transaction, the insider owned 936,410 shares in the company, valued at $5,843,198.40. This trade represents a 17.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is owned by corporate insiders.

Institutional Trading of Taysha Gene Therapies

Several large investors have recently modified their holdings of TSHA. Caitong International Asset Management Co. Ltd raised its stake in Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after purchasing an additional 4,607 shares in the last quarter. Guggenheim Capital LLC bought a new position in Taysha Gene Therapies in the 4th quarter valued at about $61,000. Panagora Asset Management Inc. acquired a new position in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $64,000. CIBC Asset Management Inc acquired a new position in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $66,000. Finally, Marex Group plc bought a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $29,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.